Valneva SE (VALN) Retained Earnings (2019 - 2026)
Valneva SE (VALN) posted Retained Earnings of $99.5 million for Q1 2026, up 2.6% sequentially from $97.0 million in Q4 2025, and up 23.76% YoY from $80.4 million in Q1 2025.
Valneva SE (VALN) Retained Earnings (2019 - 2026) Analysis & Trends
Valneva SE has reported Retained Earnings for 8 years, with the latest figure at $99.5 million in Q1 2026.
- Quarterly Retained Earnings rose 23.76% year-over-year to $99.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $99.5 million (up 23.76% YoY) and the FY2025 annual result came in at $97.0 million, up 116.24% from the prior year.
- Retained Earnings rose to $99.5 million in Q1 2026 per VALN's latest filing, from $97.0 million in the prior quarter.
- Over five years, Retained Earnings peaked at $99.5 million in Q1 2026 and troughed at -$589.5 million in Q4 2024.
- A 5-year average of $34.7 million and a median of $70.0 million in 2023 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2024: Retained Earnings jumped 121.1% in 2022, then sank 941.81% in 2024.
- Over 5 years, Retained Earnings stood at $56.4 million in 2022, then increased by 24.23% to $70.0 million in 2023, then sank by 941.81% to -$589.5 million in 2024, then soared by 116.45% to $97.0 million in 2025, then gained by 2.6% to $99.5 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered $99.5 million, $97.0 million, and $95.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Valneva SE | 618.67 Mn | 477.41 Mn | 1.86 Mn | -789.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -789.38 Mn |
| Mar 31, 2026 | 99.50 Mn |
| Dec 31, 2025 | 96.99 Mn |
| Sep 30, 2025 | 95.14 Mn |
| Jun 30, 2025 | 89.57 Mn |
| Mar 31, 2025 | 80.40 Mn |
| Dec 31, 2024 | -589.52 Mn |
| Sep 30, 2024 | 79.54 Mn |
| Jun 30, 2024 | 74.46 Mn |
| Mar 31, 2024 | 72.96 Mn |
| Dec 31, 2023 | 70.03 Mn |
| Sep 30, 2023 | 67.72 Mn |
| Jun 30, 2023 | 66.65 Mn |
| Mar 31, 2023 | 62.65 Mn |
| Dec 31, 2022 | 56.37 Mn |
| Sep 30, 2022 | 52.22 Mn |
| Jun 30, 2022 | 56.00 Mn |
| Mar 31, 2022 | 58.87 Mn |
| Dec 31, 2021 | -267.17 Mn |
| Jun 30, 2021 | 64.24 Mn |